Prognostic value of serum liver enzymes levels in type 2 diabetic patients

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 8, 2007, Pages 625-630

  Monami, Matteo ^a   Balzi, Daniela ^b   Lamanna, Caterina ^a   Melani, Cecilia ^b   Cocca, Carmen ^a   Lotti, Elena ^a   Fedeli, Angela ^a   Masotti, Giulio ^a   Marchionni, Niccolò ^a   Mannucci, Edoardo ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Unit of Epidemiology   (Italy)

Author keywords

Alanine aminotransferase; Cancer; Cardiovascular; Gamma glutamyl transpeptidase; Mortality; NAFLD

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; ITALY; LIVER CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; REGISTER; SAMPLING; SEX DIFFERENCE;

AGED; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FOLLOW-UP STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; LIVER; MIDDLE AGED; NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 36749079966     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.744     Document Type: Article

References (32)

1. Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J Intern Med 2003; 254(3): 287-295.
2. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyl-transferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004; 27(6): 1427-1432.
3. Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 2005; 28(12): 2913-2918.
4. Sattar N, Scherbakova O, Ford I, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004; 53(11): 2855-2860.
5. Hanley AJ, Williams K, Festa A, et al. Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2004; 53(10): 2623-2632.
6. Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: A 10-year follow-up of the Hoorn Study. Atherosclerosis 2006; 191(2): 391-396.
7. Targher G, Bertolini L, Poli F, et al. Nonalcoholic Fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54(12): 3541-3546.
8. Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol 2003; 17(1): 38-42.
9. Marchesini G, Avagnina S, Barantani EG, et al. Aminotransferase and ganima-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005; 28(4): 333-339.
10. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004; 2(3): 262-265.
11. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123(1): 134-140.
12. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006; 43(2): (Suppl. 1): S99-S112.
13. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005; 16(4): 421-427.
14. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44(4): 865-873.
15. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129(1): 113-121.
16. Jepsen P, Vilstrup H, Mellemkjaer L, et al. Prognosis of patients with a diagnosis of fatty liver-a registry-based cohort study. Hepatogastroenterology 2003; 50(54): 2101-2104.
17. Chalmers J, MacMahon S, Mancia G, et al, Guidelines Subcommittee of the World Health Organization. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Clin Exp Hypertens 1999; 21(5-6): 1009-1060.
18. Blackburn H. Electrocardiographic classification for population comparisons. The Minnesota code. J Electrocardiol 1969; 2(1): 5-9.
19. Charlson M, Szatrowski T, Peterson T, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
20. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-2497.
21. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14(3): 173-194.
22. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28(9): 2289-2304.
23. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem 2005; 51(6): 931-938.
24. Pompella A, Emdin M, Passino C, Paolicchi A. The significance of serum garmna-glutamyltransferase in cardiovascular diseases. Clin Chem Lab Med 2004; 42(10): 1085-1091.
25. Mazza A, Casiglia E, Scarpa R, et al. Predictors of cancer mortality in elderly subjects. Eur J Epidemiol 1999; 15(5): 421-427.
26. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006; 106(11): 2376-2381.
27. Chang CK, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia 2003; 46(5): 595-607.
28. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006; 29(2): 254-258.
29. Terry MB, Zhang FF, Kabat G, et al. Lifetime alcohol intake and breast cancer risk. Ann Epidemiol 2006; 16(3): 230-240.
30. Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140(8): 603-613.
31. Ye W, Lagergren J, Weiderpass E, Nyren O, Adami HO, Ekbom A. Alcohol abuse and the risk of pancreatic cancer. Gut 2002; 51(2): 236-239.
32. Weiderpass E, Ye W, Tamimi R, et al. Alcoholism and risk for cancer of the cervix uteri, vagina, and vulva. Cancer Epidemiol Biomarkers Prev 2001; 10(8): 899-901.